Fluticasone propionate is a potent inhaled corticosteroid used in equine medicine to treat moderate to severe equine asthma, including recurrent airway obstruction (RAO, heaves) and inflammatory airway disease (IAD). While not FDA-approved specifically for horses, inhaled fluticasone has become a mainstay of equine respiratory therapy because it delivers potent anti-inflammatory effects directly to the airways with minimal systemic absorption, reducing the side effects associated with systemic corticosteroids like dexamethasone.
Overview
Fluticasone works by binding to glucocorticoid receptors in airway epithelial cells and inflammatory cells, suppressing the production of inflammatory mediators including cytokines, prostaglandins, and leukotrienes. When delivered by inhalation, the drug achieves high local concentrations in the lungs while undergoing extensive first-pass hepatic metabolism if swallowed, resulting in very low systemic bioavailability. This makes inhaled fluticasone an attractive option for horses that need long-term anti-inflammatory airway therapy without the metabolic side effects of systemic steroids.
Administration requires a metered-dose inhaler (MDI) attached to a specially designed equine aerosol delivery device such as the Equine Haler or AeroHippus mask, which fits over one nostril and contains a valved spacer chamber.
Uses
- Recurrent Airway Obstruction (RAO) / Heaves — primary indication
- Inflammatory Airway Disease (IAD) — lower-grade airway inflammation
- Equine asthma spectrum — mild to severe forms
- Maintenance therapy — long-term airway inflammation control
- Steroid-sparing approach — alternative to systemic dexamethasone in horses at risk of laminitis
Dosage
Follow your veterinarian’s protocol. Dosing is empirical and based on clinical response.
| Severity | Dose (per nostril) | Frequency | Device |
|---|---|---|---|
| Mild-moderate | 2000-3000 mcg/day (total) | Twice daily | Equine Haler or AeroHippus with MDI |
| Severe / initial stabilization | 3000-6000 mcg/day (total) | Twice daily | Equine Haler or AeroHippus with MDI |
| Maintenance | Lowest effective dose | Once or twice daily | Equine Haler or AeroHippus with MDI |
Each actuation of a Flovent HFA 220 mcg inhaler delivers 220 mcg of fluticasone. A typical dose may involve 5-6 actuations per nostril, twice daily. Treatment is generally started at higher doses during acute exacerbations and tapered to a maintenance dose once clinical improvement is seen.
Administration technique is critical. The mask must form a good seal over the nostril, the horse should breathe through the device for at least 5-10 breaths per actuation, and the spacer should be primed before first use. Poor technique results in inadequate drug delivery and treatment failure.
Side Effects
| Common | Rare / Potential Concerns |
|---|---|
| Local fungal infection of the upper airway (rare at equine doses) | Adrenal suppression at high doses or with concurrent systemic steroids |
| Mild irritation or headshaking during administration | Immunosuppression (rare with inhaled route) |
| Laminitis risk (much lower than systemic corticosteroids, but not zero) |
Inhaled fluticasone is generally very well tolerated. The risk of systemic side effects, including laminitis and adrenal suppression, is substantially lower than with systemic dexamethasone or prednisolone. However, at very high doses or with prolonged use, some systemic absorption does occur.
Drug Interactions
- Systemic corticosteroids (dexamethasone): Additive effects; monitor for adrenal suppression if combining.
- Inhaled bronchodilators (albuterol/salbutamol): Often used together. Administer the bronchodilator first to open airways, then follow with fluticasone 10-15 minutes later for better drug deposition.
- Clenbuterol (oral bronchodilator): May be used concurrently during the transition to inhaled therapy.
Contraindications
- Active respiratory infection (bacterial or fungal) — corticosteroids may worsen infection without concurrent antimicrobial therapy
- Horses unable to tolerate the mask/device
- Known hypersensitivity to fluticasone
- Caution in horses with a history of laminitis (lower risk than systemic steroids but not zero)
Storage
- Store the MDI at room temperature, 59-86 degrees F (15-30 degrees C).
- Do not puncture or expose to high heat.
- Keep the Equine Haler/AeroHippus device clean; wash the spacer regularly per manufacturer instructions.
- Track remaining doses; MDIs do not always indicate when empty.
Frequently Asked Questions
How long before I see improvement with inhaled fluticasone? Some improvement may be seen within days, but the full anti-inflammatory benefit may take 1-2 weeks. Corticosteroids address underlying inflammation, so the response is not as immediate as a bronchodilator.
Is inhaled fluticasone safer than dexamethasone injections? Inhaled fluticasone delivers the drug locally to the lungs with minimal systemic effects. Systemic dexamethasone is effective but carries higher risks of laminitis, immunosuppression, and adrenal suppression, especially with repeated dosing. Many veterinarians prefer the inhaled route for long-term management.
How expensive is inhaled therapy for horses? The cost includes the aerosol delivery device (one-time purchase, roughly $500-700) and the MDI canisters ($50-200 each depending on pharmacy). Monthly costs can range from $100-400 depending on the dose required. Discuss cost management with your veterinarian.
Do I still need to manage my horse’s environment? Yes. Environmental management (reduced dust, soaked or steamed hay, good ventilation, turnout) is the cornerstone of equine asthma management and should always accompany any drug therapy.
This information is for educational purposes only and does not replace professional veterinary advice. Always consult your veterinarian before administering any medication to your horse.